Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This Traditional Chinese Medicine (TCM) formulation was developed by the First Affiliated Hospital of Xi'an Jiaotong University specifically for the treatment of COVID-19. It is a liquid decoction designed to leverage the anti-infective and anti-inflammatory properties of traditional herbal medicine, which has a long history of use in treating upper respiratory tract infections. In clinical practice, the formulation is administered orally as a 150 ml liquid dose twice daily for a duration of seven days. The primary therapeutic goal is to evaluate its efficacy in managing SARS-CoV-2 infection by reducing inflammation and alleviating symptoms associated with the virus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Traditional Chinese Medicine Formulation (First Affiliated Hospital Xi'an Jiaotong University).